SF3B1 and myelodysplastic syndrome: To enhance diagnostic accuracy, the 2016 WHO Classification incorporated molecular data into MDS diagnosis and management [3], notably identifying MDS with ring sideroblasts (MDS-RS) by SF3B1 mutations and ≥5% ring sideroblasts.